According to the World Health Organization, 39.9 million people were living with HIV globally in 2023. Out of this, 38.6 million were adults and 53% of the infected people were women and girls. Studies suggest that approximately 5.4 million people aren’t aware that they have HIV. The common treatment for human immunodeficiency virus infection includes antiretroviral therapy (ART). This therapy involves taking a combination of HIV medicines every day. Several clinical trials are ongoing to develop innovative human immunodeficiency virus (HIV 1) infection therapeutics to improve and manage the condition including islatravir, and fostemsavir among others.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing human immunodeficiency virus (HIV 1) infection development activities is covered in the report.
Currently, there is no cure for HIV. However, there are several human immunodeficiency virus (HIV 1) infection therapeutic drugs available to slow down the progression of HIV. The infection is treated with a combination of medicines, administered orally every day. Taking a combination of medicines is the most effective way to keep HIV from multiplying and destroying the cells. There are several types of ART including nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, pharmacokinetic enhancers, integrase strand transfer inhibitors, and non-nucleoside reverse transcriptase inhibitors among others. As HIV infection is a major health issue, the development of new human immunodeficiency virus (HIV 1) infection drug candidates is crucial for the management of the disease. The focus areas of clinical trials include antiretroviral therapies and vaccines among others. For instance, Vir Biotechnology, Inc. is evaluating the safety of prototype human CMV-based vaccine to manage human immunodeficiency virus infection. These dynamics are impacting the clinical trial landscape significantly.
This product will be delivered within 3-5 business days.
Report Coverage
The Human Immunodeficiency Virus (HIV 1) Infection Pipeline Report by the publisher gives comprehensive insights into Human Immunodeficiency Virus (HIV 1) Infection drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for human immunodeficiency virus (HIV 1) infection. The human immunodeficiency virus (HIV 1) infection pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies . It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from human immunodeficiency virus (HIV 1) infection.The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing human immunodeficiency virus (HIV 1) infection development activities is covered in the report.
Human Immunodeficiency Virus (HIV 1) Infection Drug Pipeline Outlook
HIV stands for human immunodeficiency virus, which infects cells of the immune system and makes the body weak to fight against various diseases. When HIV has severely weakened the immune system, it can lead to AIDS (acquired immunodeficiency syndrome). Human immunodeficiency virus infects the white blood cells of the immune system called CD4 cells, destroys them and causes a drop in the white blood cell count. At an initial level, HIV makes the infected person sick with flu-like symptoms and hides in the body for a long without any noticeable symptoms. The virus slowly destroys the T-cells at this phase. When numbers of T-cells get very low, it indicates that HIV has progressed to AIDS.Currently, there is no cure for HIV. However, there are several human immunodeficiency virus (HIV 1) infection therapeutic drugs available to slow down the progression of HIV. The infection is treated with a combination of medicines, administered orally every day. Taking a combination of medicines is the most effective way to keep HIV from multiplying and destroying the cells. There are several types of ART including nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, pharmacokinetic enhancers, integrase strand transfer inhibitors, and non-nucleoside reverse transcriptase inhibitors among others. As HIV infection is a major health issue, the development of new human immunodeficiency virus (HIV 1) infection drug candidates is crucial for the management of the disease. The focus areas of clinical trials include antiretroviral therapies and vaccines among others. For instance, Vir Biotechnology, Inc. is evaluating the safety of prototype human CMV-based vaccine to manage human immunodeficiency virus infection. These dynamics are impacting the clinical trial landscape significantly.
Human Immunodeficiency Virus (HIV 1) Infection - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of human immunodeficiency virus (HIV 1) infection emerging drugs based on several segmentations including:By Phase
The pipeline assessment report covers 50+ drug analyses based on phase.- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The human immunodeficiency virus (HIV 1) infection therapeutic assessment covers 50+ drug analyses based on drug classes:
- Monoclonal Antibody
- Peptides
- Small Molecule
By Route of Administration
The human immunodeficiency virus (HIV 1) infection clinical assessment report covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
Human Immunodeficiency Virus (HIV 1) Infection - Pipeline Assessment Segmentation, By Phases
The human immunodeficiency virus (HIV 1) infection report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase I covers a major share of the total clinical trials for human immunodeficiency virus.Human Immunodeficiency Virus (HIV 1) Infection - Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under human immunodeficiency virus (HIV 1) infection pipeline analysis include monoclonal antibodies, peptides, and small molecules. International AIDS Vaccine Initiative is currently evaluating the safety of PGT121 monoclonal antibody for HIV prevention and therapy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for human immunodeficiency virus (HIV 1) infection.Human Immunodeficiency Virus (HIV 1) Infection Clinical Trials Assessment - Competitive Dynamics
The human immunodeficiency virus (HIV 1) infection report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in human immunodeficiency virus (HIV 1) infection clinical trials:- Tibotec Pharmaceuticals
- Vir Biotechnology, Inc.
- Janssen Research & Development, LLC
- ViiV Healthcare
- Janssen-Cilag S.p.A.
- Seagen Inc.
- Merck Sharp & Dohme LLC
- Johnson & Johnson Pte Ltd
- Sangamo Therapeutics
- TaiMed Biologics Inc.
- AbbVie
- Gilead Sciences
- Alexion Pharmaceuticals, Inc.
- Abbott
- Others
Tibotec Pharmaceuticals
Vir Biotechnology, Inc.
Janssen Research & Development, LLC
ViiV Healthcare
Janssen-Cilag S.p.A.Seagen Inc.
Merck Sharp & Dohme LLC
Johnson & Johnson Pte Ltd
Sangamo Therapeutics
TaiMed Biologics Inc.
AbbVie
Gilead Sciences
Alexion Pharmaceuticals, Inc.
Abbott
Others
Human Immunodeficiency Virus (HIV 1) Infection - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and human immunodeficiency virus (HIV 1) infection therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming human immunodeficiency virus (HIV 1) infection drug candidates.Drug: ABBV-181
The trial is designed to test the safety of pharmacokinetics and pharmacodynamics of ABBV-181, a drug designed for human immunodeficiency virus-1 infected participants who are taking antiretroviral therapy. The trial is sponsored by AbbVie and is currently under phase I.Drug: Doravirine, Tenofovir, Lamivudine
The objective of the study is to compare the antiretroviral activity of three drugs, namely, oravirine, tenofovir, and lamivudine in participants infected with the human immunodeficiency virus. The trial is sponsored by Merck Sharp & Dohme LLC and is currently under phase III.Drug: Cabotegravir
ViiV Healthcare is developing this human immunodeficiency virus (HIV 1) infection drug candidate and is currently under phase III. The study is being conducted to evaluate the safety of the drug in patients receiving CAB and RPV LA injections.Reasons To Buy This Report
The Human Immunodeficiency Virus (HIV 1) Infection Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for human immunodeficiency virus (HIV 1) infection. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into human immunodeficiency virus (HIV 1) infection funding, market trends, regulatory environments, and potential growth opportunities within the human immunodeficiency virus (HIV 1) infection pipeline insights.Key Questions Answered in the Human Immunodeficiency Virus (HIV 1) Infection - Pipeline Assessment Report
- What is the current landscape of human immunodeficiency virus (HIV 1) infection disease pipeline drugs?
- Which companies/institutions are developing human immunodeficiency virus (HIV 1) infection disease emerging drugs?
- How many phase II drugs are currently present in human immunodeficiency virus (HIV 1) infection disease pipeline drugs?
- Which company is leading the human immunodeficiency virus (HIV 1) infection disease pipeline development activities?
- What is the current human immunodeficiency virus (HIV 1) infection disease therapeutic assessment?
- What are the opportunities and challenges present in the human immunodeficiency virus (HIV 1) infection disease drug pipeline landscape?
- What is the efficacy and safety profile of human immunodeficiency virus (HIV 1) infection disease pipeline drugs?
- Which companies/institutions are involved in human immunodeficiency virus (HIV 1) infection disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in human immunodeficiency virus (HIV 1) infection disease?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Human Papillomavirus (HPV)
4 Patient Profile: Human Papillomavirus (HPV)
5 Human Papillomavirus (HPV): Epidemiology Snapshot
6 Human Papillomavirus (HPV): Market Dynamics
7 Human Papillomavirus (HPV): Key Facts Covered
8 Human Papillomavirus (HPV), Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Human Papillomavirus (HPV) Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Human Papillomavirus (HPV) Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Human Papillomavirus (HPV) Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Human Papillomavirus (HPV) Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Human Papillomavirus (HPV), Key Drug Pipeline Companies
